The earliest studies of clonidine in the treatment of alcohol withdrawal were limited by the use of concomitant medications. Bjorkqvist et al. evaluated the efficacy of a clonidine taper ...

Objectives To investigate the efficacy and safety of subcutaneous clonidine for refractory symptoms in the palliative setting. Methods A retrospective chart review of the use of subcutaneous clonidine ...

The HCL journey has been relentless, gratifying and marked with a series of achievements. Our unified efforts have catapulted the company from a garage start-up to a conglomerate whose businesses span ...

Bonus Dec 05, 2019 Dec 07, 2019 Oct 23, 2019 Bonus Ratio: 1 share(s) for every 1 shares held Bonus Mar 19, 2015 Mar 20, 2015 Jan 30, 2015 Bonus Ratio: 1 share(s) for every 1 shares held Bonus Mar 15, ...

Bonus May 05, 1995 Jun 01, 1995 Feb 16, 1995 Bonus Ratio: 1 share(s) for every 2 shares held Rights Aug 07, 1992 Sep 01, 1992 Sep 30, 1992 Rights ratio: 1 share for every 1 held at a price of Rs 60.0 ...

David Coghill; Tobias Banaschewski; Alessandro Zuddas; Antonio Pelaz; Antonella Gagliano; Manfred Doepfner ...

The treatment, Lucemyra (lofexidine hydrochloride), was found to be able ... In the results, the treatment was found to be superior to clonidine, which is commonly used off-label for opioid ...

HCLTech is proud to be a gold sponsor of #PPCC24. Visit us at booth 313 and see how we are redefining business performance for our customers from cloud strategy to AI-led transformations.

These LCAs are being displayed in accordance with U.S. Department of Labor regulations. Please note that these LCAs are posted in connection with the intended employment of foreign national workers.